News about Global Pharma

Johnson & Johnson Gets US FDA Approval for TREMFYA

TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.

Global Pharma | 12/09/2024 | By Aishwarya |  489

GenNext and Agilent to Boost High-Value Decision Making in Biopharmaceutical Research

The integration of GenNext's AutoFox Protein Footprinting System with Agilent's 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System presents an unparalleled approach to detailed protein structure analysis and biomolecular interaction studies.

Global Pharma | 12/09/2024 | By Aishwarya |  593

Synaptogenix Raises USD 5 Million in Financing

Synaptogenix, Inc. has secured USD 5 million in financing through a combination of a registered public offering and a private placement.

Global Pharma | 12/09/2024 | By Aishwarya |  523

Roche Inaugurates Pharma Research and Development Center in Basel

Roche has launched its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland.

Global Pharma | 11/09/2024 | By Aishwarya |  1190

Strides Gets Approval from Equity Shareholders for Launch of OneSource

This is a critical step in the creation of OneSource and the support from Shareholders and Secured Creditors underscores the confidence in the company’s strategic initiative to create OneSource - India’s first specialty pharma Contract Development and Manufacturing Organization (CDMO).

Global Pharma | 11/09/2024 | By Aishwarya |  1040

Aisa Pharma Gets FDA Orphan Drug Designation for AISA-021

Aisa is developing AISA-021 for the treatment of Systemic Sclerosis (SSc), a rare disease, which impacts approximately 175,000 Americans and has the highest mortality rate of any autoimmune disease.

Global Pharma | 10/09/2024 | By Aishwarya |  1402

GC Biopharma Rolls Out ALYGLO for Treatment of Primary Humoral Immunodeficiency

ALYGLO, an immune globulin formulation, has met the primary endpoints for both safety and efficacy as established by the FDA-recommended guidelines in our Phase 3 clinical trials.

Global Pharma | 09/09/2024 | By Aishwarya |  639

Akums Appoints Shantanu R Chobhe as Corporate Quality Assurance Head

At Akums, Chobhe will take charge of all quality assurance (QA) and quality control (QC) departments, overseeing both active pharmaceutical ingredients (API) and formulations.

Global Pharma | 06/09/2024 | By Aishwarya |  676

Moderna Gets MHRA Authorization for Updated COVID-19 Vaccine

For the first time in the UK, the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program.

Global Pharma | 05/09/2024 | By Aishwarya |  481

Olon to Advance API Production with HuvePharma Italia Acquisition

The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio plant and, through the development of new business opportunities, bring it to full production capacity.

Global Pharma | 05/09/2024 | By Aishwarya |  784